Patents by Inventor Daniel David Sternbach

Daniel David Sternbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
    Patent number: 7449468
    Abstract: The present invention provides a compound of formula (I): wherein R1-R5, R25, R26, Y, y, and X2are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: November 11, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Pierette Banker, Rodolfo Cadilla, Millard Hurst Lambert, III, Stephen William Rafferty, Daniel David Sternbach, Marcos Luis Sznaidman
  • Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
    Patent number: 7229998
    Abstract: The present invention provides a compound of formula (I): wherein R1–R5, R25, R26, Y and X2 are as defined herein. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and are useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: June 12, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Rodolfo Cadilla, Millard Hurst Lambert, III, Stephen William Rafferty, Daniel David Sternbach
  • Activator of PPAR delta
    Patent number: 6723740
    Abstract: Compounds of Formula (I) are disclosed. These compounds selected activators of human PPAR delta.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: April 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Esther Yu-Hsuan Chao, Curt Dale Haffner, Millard Hurst Lambert, III, Patrick Reed Maloney, Michael Lawrence Sierra, Daniel David Sternbach, Marcos Luis Sznaidman, Timothy Mark Willson, Huaqiang Eric Xu
  • Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
    Publication number: 20040072838
    Abstract: The present invention provides a compound of formula (1) wherein R1-R5, R25, R26, Y and X2 are defined as in claim 1. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and arc useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia.
    Type: Application
    Filed: October 31, 2003
    Publication date: April 15, 2004
    Inventors: Pierette Banker, Rodolfo Cadilla, Millard Hurst Lambert lll, Stephen William Rafferty, Daniel David Sternbach, Marcos Luis Sznaidman
  • Activators of PPAR delta
    Patent number: 6710063
    Abstract: Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 23, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Esther Yu-Hsuan Chao, Curt Dale Haffner, Millard Hurst Lambert, III, Patrick Reed Maloney, Michael Lawrence Sierra, Daniel David Sternbach, Marcos Luis Sznaidman, Timothy Mark Willson, Huaqiang Eric Xu
  • Activator of PPAR delta
    Publication number: 20030203947
    Abstract: Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.
    Type: Application
    Filed: March 6, 2003
    Publication date: October 30, 2003
    Inventors: Esther Yu-Hsuan Chao, Curt Dale Haffner, Millard Hurst Lambert, Patrick Reed Maloney, Michael Lawrence Sierra, Daniel David Sternbach, Marcos Luis Sznaidman, Timothy Mark Willson, Huaqiang Eric Xu
  • Water soluble camptothecin derivatives
    Patent number: 6100273
    Abstract: The present invention relates to water soluble, camptothecin derivatives of formula (I). ##STR1## wherein A represents a moiety of the formula (IIA), (IIB) or (IIC): ##STR2## X is selected from the group consisting of alkyl, aryl, (CH.sub.2).sub.m OR.sup.1, (CH.sub.2).sub.m SR.sup.1 and (CH.sub.2).sub.m NR.sup.1 R.sup.2 wherein m is an integer of 0 to 6, and R.sup.1 and R.sup.2 are hydrogen, lower alkyl, aryl or together with the nitrogen form a 5-7 membered ring; q is an integer of 0 to 2; n represents the integer 1 or 2; p is an integer of 1 to 6; Y and W are selected from the group consisting of alkyl, aryl, alkoxy, aryloxy and amino, Q is oxygen or sulfur; P is phosphorus; J represents the atoms necessary to complete a 5 or 6 membered aromatic ring; and the pharmaceutically acceptable salts thereof; their use as topoisomerase inhibitors, their preparation; and their use in the treatment of cancer.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: August 8, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Jeffrey Mark Besterman, Michael Glenn Evans, Karen Elizabeth Lackey, Michael Joseph Luzzio, Michael Robert Peel, Daniel David Sternbach